Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Alterity Therapeutics and keeping the price target at $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors demonstrated by Alterity Therapeutics in their recent clinical trials. The company’s presentation at the 2025 International Congress of Parkinson’s Disease and Movement Disorders highlighted positive data from their Phase 2 study of ATH434 in Multiple System Atrophy (MSA). The study showed that ATH434 significantly slowed disease progression and improved symptoms such as orthostatic hypotension, with the 50mg dose achieving a 48% treatment effect and the 75mg dose showing a 35% effect after adjusting for baseline differences.
Additionally, the drug demonstrated improvements in clinical severity scores and increased patient activity levels, as well as neuroimaging data confirming target engagement by reducing iron accumulation in specific brain regions. Importantly, ATH434 was well tolerated with no serious treatment-related adverse events. These promising results suggest a strong potential for ATH434 in treating MSA, supporting McCarthy’s positive outlook and Buy rating for Alterity Therapeutics’ stock.
According to TipRanks, McCarthy is an analyst with an average return of -11.6% and a 38.63% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Atossa Therapeutics, and SCYNEXIS.